We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Vircell Showcases Powerful Automation System and Ready-To-Use Diagnostic Kits at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022

Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Vircell (Granada, Spain) is participating in this year's edition of MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At MEDICA 2022, Vircell is showcasing its all-in-one CLIA system, VIRCLIA LOTUS which is designed for the automatization of infectious serology with the VirCia Monotest kits. Vircell’s AmpliRun Total Controls are external run controls to monitor the accuracy and precision of the complete analytical process (extraction & amplification). These noninfectious lyophilized run controls include the complete inactivated microorganism in a matrix that mimics human specimens. In combination with the VirClia Monotests, laboratories can daily process a large panel of more than 80 tests with complete traceability. Thanks to the versatility of the VIRCLIA LOTUS fully-automated chemiluminescence solution and wide range of tests for infectious serology, laboratories can process their analysis on a daily basis, without the need to batch samples or refer them to outside centers.

Vircell is also highlighting its VIRPLEX Real Time PCR kits for infectious diseases testing alongside the Aspergillus Galactomannan Ag VIRCLIA Monotest. The test uses sandwich chemiluminescent immunoassay (CLIA) technology for the detection of Aspergillus galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples.

Related Links:
Vircell

Visit expo >

Gold Member

Flocked Fiber Swabs

Puritan® Patented HydraFlock®

Online QC Software
Acusera 24•7

All-in-One Molecular System

AIO M160

Hematology Consumables

Bioblood Devices

Latest MEDICA 2022 News

Channels

Clinical Chemistry

view channel

Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s

Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. Earlier detection,... Read more

Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation

The TOBY Test for Alzheimer’s Disease from TOBY, Inc. (Austin, TX, USA) has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation as an aid in the diagnosis of Alzheimer’s disease.... Read more

Image: Primary central nervous system lymphoma (PCNSL) is a rare malignancy of the brain, spinal cord, and eyes that is often diagnosed late and associated with poor outcomes (Photo courtesy of Tdvorak / Wikimedia Commons / CC BY-SA 3.0)

Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma

Primary central nervous system lymphoma (PCNSL) is a rare malignancy of the brain, spinal cord, and eyes with delayed diagnosis and poor outcomes. Current fluid-based testing using interleukin measurements... Read more

Molecular Diagnostics

view channel

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests

Cancer screening is intended to reduce mortality, but policy decisions often depend on early indicators that may not fully reflect true survival benefit. The emergence of blood-based tests capable of detecting... Read more

Gene Fusion Patterns May Flag High Risk Solitary Fibrous Tumors

Solitary fibrous tumor (SFT) is a rare subtype of sarcoma, a cancer that develops in connective tissues such as fat, muscle, blood vessels, and fibrous tissue. SFTs most commonly arise in the chest cavity... Read more

Image: The new RNA origami method achieved 18-nucleotide resolution, enough to distinguish healthy from disease-associated repeat sections (image credit: Adobe Stock)

New RNA Origami Method Supports Faster Targeted Testing for Repeat Expansion Disorders

Repeat expansion disorders drive conditions such as myotonic dystrophy, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), yet accurately sizing the mutated sequences remains difficult.... Read more

Hematology

view channel

Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children

Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more

Image: Graphical abstract (Waclawiczek A, Leppä AM, Renders S, et al. Cell Stem Cell, 2026. doi:10.1016/j.stem.2026.04.012)

Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more

Advanced CBC-Derived Indices Integrated into Hematology Platforms

Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more

Blood Test Enables Early Detection of Multiple Myeloma Relapse

Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more

Immunology

view channel

Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more

Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring

Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read more

Routine TB Screening Test May Reveal Immune Aging and Mortality Risk

Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more

Biomarkers and Molecular Testing Advance Precision Allergy Care

Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more

Microbiology

view channel

FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets

Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read more

New AMR Assay Supports Rapid Infection Control Screening in Hospitals

As antimicrobial resistance spreads worldwide, healthcare-associated infections are placing a growing burden on hospitals, increasing the need for faster and broader diagnostic solutions.... Read more

Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo

In eastern Democratic Republic of the Congo, communities are confronting a resurgence of Bundibugyo ebolavirus, a rarer species for which no vaccines or treatments have been approved. Ebola is a highly... Read more

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more

Pathology

view channel

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more

Image: Graphical Abstract (Eldad D. Shulman et al., AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology, Cell (2026). DOI: 10.1016/j.cell.2026.04.023)

Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images

Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more

AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification

Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read more

FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification

Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more

Technology

view channel

AI-Enabled Assistant Unifies Molecular Workflow Planning and Support

Clinical laboratories and research groups face increasingly complex molecular workflows and expanding technical documentation spread across multiple systems. Fragmented digital tools can slow experiment... Read more

AI Tool Automates Validation of Laboratory Software Configuration Changes

Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read more

Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease

Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more

Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing

Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more

Industry

view channel

New Distribution Agreement Expands Access to CE-Marked Precision Oncology Assays

Eurobio Scientific (Les Ulis, France) has signed a distribution agreement with Canhelp Genomics (Hangzhou, China) to broaden availability of the Canhelp‑UCa and Canhelp‑Origin assays. The agreement extends... Read more

Image: Artera’s multi-modal AI platform analyzes digital pathology and clinical data to support personalized cancer management (photo courtesy of Artera)

Artera to Highlight AI-Based Cancer Risk Stratification at ASCO 2026

Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform will be featured in multiple presentations at the ASCO 2026 Annual Meeting, taking place May 29–June 2 in Chicago.... Read more

Natera to Present Data on MRD-Guided Cancer Care at ASCO 2026

Natera, Inc. (Austin, TX, USA), a company focused on cell-free DNA testing and precision medicine, announced an oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting,... Read more

Fujifilm Integrates Structured Reporting into Digital Pathology Workflow

FUJIFILM Healthcare Americas Corporation (Lexington, MA, USA) and mTuitive (Centerville, MA, USA) have formed a strategic partnership to integrate mTuitive’s structured pathology reporting platform with... Read more